Opportunity

Simpler Grants.gov #360625

NIH NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Research Funding Opportunity

Buyer

National Institutes of Health

Posted

September 18, 2025

Identifier

360625

NAICS

541715

This opportunity is a research funding announcement from the National Institutes of Health (NIH), specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to establish the Disorders of Gastrointestinal Interoception Consortium (DGIC). - Government Buyer: - National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Purpose: - Establish the DGIC, expanding research beyond gastroparesis to a broader range of adult and pediatric gastrointestinal (GI) conditions involving impaired interoceptive processing - Support up to six Clinical Research Centers and one Scientific Data Research Center - Funding Details: - Total estimated funding: $3,000,000 - Open to educational institutions, government entities, nonprofits, businesses, and foreign organizations - Products/Services Requested: - Multidisciplinary research projects focused on mechanisms, biomarkers, and therapeutic targets for GI interoception disorders - Unique/Notable Requirements: - Emphasis on collaborative, multi-center research - Inclusion of both adult and pediatric GI conditions - No specific OEMs, products, or vendors are requested, as this is a research grant opportunity

Description

The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) seeks to continue and expand the work of the Gastroparesis Consortium to include other adult and pediatric gastrointestinal conditions associated with impaired interoceptive processing. The initiative aims to form a Disorders of Gastrointestinal Interoception Consortium (DGIC) consisting of up to 6 Clinical Research Centers and a Scientific Data Research Center. The consortium will focus on multidisciplinary approaches to understand underlying mechanisms, identify biomarkers for treatment efficacy, and discover novel therapeutic targets for future clinical trials. The funding supports cooperative agreements to advance research in gastrointestinal interoception disorders.

View original listing